Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jul 27;2(4):290-3.
doi: 10.1016/j.jdcr.2016.06.004. eCollection 2016 Jul.

Pembrolizumab-associated sarcoidosis

Jonathan Cotliar  1 , Christiane Querfeld  2 , William J Boswell  3 , Naveen Raja  4 , Dan Raz  5 , Robert Chen  6
Affiliations
Case Reports

Pembrolizumab-associated sarcoidosis

Jonathan Cotliar et al. JAAD Case Rep. .
No abstract available

Keywords: FDG, fludeoxyglucose; PD-1, programmed cell death-1; lymphoma; pembrolizumab; programmed cell death-1; sarcoidosis.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Clinical presentation. A, Nontender subcutaneous nodule of right forearm without overlying erythema while taking pembrolizumab for refractory Hodgkin lymphoma. B, Resolution of right forearm subcutaneous nodule while not taking pembrolizumab during course of prednisone.
Fig 2
Fig 2
Microscopic examination. A, Normal epidermis with mild perivascular lymphohistiocytic inflammation. B, Focal dermal epithelioid granuloma. (A and B, Hematoxylin-eosin stain; original magnifications: A, ×10; B, ×20.)
Fig 3
Fig 3
Radiographic examination. Positron emission tomography while taking pembrolizumab shows uptake within left scapula (A), sternum, hilar/mediastinal lymph nodes (B). Resolution of left scapula lesion (C), sternal lesion, and adenopathy (D) while not taking pembrolizumab during prednisone course.
See this image and copyright information in PMC

References

    1. Naidoo J., Page D.B., Li B.T. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–2391. - PMC - PubMed
    1. Matsumura N., Ohtsuka M., Kikuchi N., Yamamoto T. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. Acta Derm Venereol. 2016;96:259–260. - PubMed
    1. Kato Y., Otsuka A., Miyachi Y., Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2015 - PubMed
    1. Ohtsuka M., Miura T., Mori T., Ishikawa M., Yamamoto T. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma. JAMA Dermatol. 2015;151:797–799. - PubMed
    1. Goldinger S.M., Stieger P., Meier B. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016 [Epub ahead of print] - PubMed

Publication types

LinkOut - more resources